There is no cure for dermatomyositis, but treatment can improve a patient’s skin and muscle strength and function. By treatment type, market is segmented by Anti-inflammatory medications, Immunosuppressive drugs, Immunoglobulin, and Others (Plasma Exchange, Monoclonal antibody among others). Some major factors involved in driving the market growth include development of novel treatment for the treatment of dermatomyositis by key players, increasing research and development for dermatomyositis and product launches by major players in market, increasing clinical trials by market players, and others.
Additionally, increasing funding by the government for clinical research is expected to propel the global dermatomyositis market over the forecast period. For instance, according to the data published by the Pharmaphorum in July 2022, the U.K government added US$ 212 million funding for clinical research, and to strengthen the national data infrastructure.
Global dermatomyositis market is estimated to be valued at US$ 493.15 million in 2022 and is expected to reach US$ 696.57 million by 2030, witnessing a CAGR of 4.4% over the forecast period (2022-2030).
Figure 1. Global Dermatomyositis Market Share (%), By Region, 2022
To learn more about this report, request a free sample copy
Increasing funding by non-profit organizations is expected to drive growth of the global dermatomyositis market.
The increasing number of research funding by governments and non-profit organizations of various countries for dermatomyositis or inflammatory myopathies treatment is expected to drive growth of the global dermatomyositis market over the forecast period.
For instance, in 2021, The Myositis Association, a non-profit organization dedicated to improving the lives of people affected by myositis, sponsoring creative research, and raising myositis awareness and activism, funded two research grants. A pilot study grant of US$ 200,000 had been provided to Dr. Kanneboyina Nagaraju, DVM, PhD of Binghamton University in New York. Dr. Nagarahu’s research will focus on inflammatory muscle changes seen in Dermatomyositis and Polymyositis and their similarity to those seen in viral infections. The study will evaluate whether this inflammation can be blocked using viral proteins. If successful, it could open up a new strategy for potential treatments.
Moreover, in May 2020, The Myositis Association (TMA) announced that recipients of the TMA's Innovative Research Grant, Professor Ian Hampson, Dr. Janine Lamb, and Dr. Spyridon Megremis at the University of Manchester had developed a novel approach to identify the targets of antibodies produced by the immune system in myositis patients. Dr. Lamb and the team analyzed antibodies and autoantibodies that accumulated throughout life in individuals with dermatomyositis, a rare autoimmune inflammatory muscle disease. Dermatomyositis is often marked by a distinctive skin rash and can affect both adults and children.
Dermatomyositis Market Report Coverage
|Market Size in 2022:
|US$ 493.15 Mn
|Historical Data for:
|2017 to 2020
|2022 to 2030
|Forecast Period 2022 to 2030 CAGR:
|2030 Value Projection:
|US$ 696.57 Mn
AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Néovacs, Horizon Therapeutics plc., and Pfizer Inc.
|Restraints & Challenges:
Figure 2. Global Dermatomyositis Market Share (%) Analysis, By Treatment Type, 2022
To learn more about this report, request a free sample copy
Increasing incidence of dermatomyositis is expected to drive growth of the global dermatomyositis market.
Increasing incidence of the juvenile dermatomyositis is expected to fuel the market growth over the forecast period. For instance, according to the data published by the Orphanet in March 2021, the annual incidence of Juvenile dermatomyositis (JDM) is 1 per 250,000-500,000 children. Females are affected more frequently than males (2-5:1 ratio).
Moreover, according to National Organization for Rare Disorders (NORD), 2021, the global incidence of dermatomyositis was estimated to be 9.63 cases per million people every year. The symptoms typically start to show in children between the ages of 5 and 15. Juvenile dermatomyositis affects approximately 3 in 1,000,000 children.
Global Dermatomyositis Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments of countries, restricted movement, and other COVID-19 safety precautions.
Moreover, the coronavirus pandemic has had a negative impact on the development, production, and supply of pharmaceutical products used in the treatment of various diseases in North America, Europe, and Asia Pacific. The supply and production of pharmaceutical products are affected due to the imposition of lockdown during the COVID-19 pandemic. This lockdown has resulted in the closure of industrial establishments, except the manufacturing of essential commodities, and disruption in the supply chain of pharmaceutical products.
Furthermore, according to ScienceDirect Journal, a journal of scientific publications, an article published in June 2021 about the impact of the COVID-19 pandemic on pharmaceutical systems and supply chains, the negative impact on the access and availability of essential medicines, particularly pharmaceutical products and antimicrobials, has been reported. Due to reduced inter-country transfer of products and services, as well as limited in-country capacity and manufacturing capabilities, most medical stores had extended lead times.
Global Dermatomyositis Market: Restraint
The drugs used for the treatment of dermatomyositis may cause some side effects or adverse events, which is expected to hinder the global dermatomyositis market growth over the forecast period
For instance, the drug Octagam 10% (Immune globulin (human)) approved for adult dermatomyositis causes headache, nausea, anaphylactic reactions, thrombosis, and in rare cases may cause side effects such as hemolytic anemia, aseptic meningitis syndrome, and transfusion-related acute lung injury (TRALI)
Some of the common side effects of Dermatomyositis drugs are: Pain and swelling at injection site, mild headache, fainting and dizziness, back pain, abdominal pain and muscle cramps, and minor chest pain.
Major players operating in the global dermatomyositis market include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc, Néovacs, Horizon Therapeutics plc, and Pfizer Inc.
Frequently Asked Questions